REGENXBIO Inc. announced that interim data from the Phase II ALTITUDE® trial evaluating suprachoroidal delivery of surabgene lomparvovec (ABBV-RGX-314, sura-vec) for the treatment of diabetic retinopathy (DR) will be presented at the American Academy of Ophthalmology 2025 Annual Meeting. Sura-vec is an investigational one-time gene therapy developed in collaboration with AbbVie and is being studied as a potential treatment for wet age-related macular degeneration (wet AMD) and DR. The results will be presented by Dr. Charles C. Wykoff on October 17, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH93932) on October 09, 2025, and is solely responsible for the information contained therein.